Q-omics provides the consensus-scored NDUFAF1 profile across patient tissues and cancer cell-line models. NDUFAF1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFAF1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, NDUFAF1 protein abundance shows 21,381 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, THCA, and LSCC as cancer lineages where NDUFAF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFAF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFAF1 survival associations across molecular data types. NDUFAF1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFAF1 RNA expression–survival associations across cancer types. High NDUFAF1 expression shows unfavorable associations in UVM and HNSC, but favorable associations in KIRP, MESO, LIHC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFAF1 RNA expression.
This table summarizes NDUFAF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFAF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFAF1 shows lower tumor expression in THCA, KIRP, HNSC, KIRC and KICH and higher tumor expression in LIHC. The THCA box plot shows higher NDUFAF1 RNA expression in normal versus tumor tissue (log2 FC = −0.699, t-test p < 0.001).
This table shows molecular features associated with NDUFAF1 in patient tissues and cancer cell lines. In patient samples, NDUFAF1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFAF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
